Prestige Consumer Healthcare Inc. (New York Stock Exchange:PBH)
| Market Cap | 2.22B-25.9% |
| Revenue (ttm) | 1.10B-1.4% |
| Net Income | 172.01M-19.2% |
| EPS | 3.57-16.2% |
| Shares Out | 47.37M |
| PE Ratio | 13.07 |
| Forward PE | 9.14 |
| Dividend | n/a |
| Ex-Dividend Date | Sep 27, 2018 |
| Volume | 86,687 |
| Open | 47.28 |
| Previous Close | 47.57 |
| Day's Range | 46.76 - 47.37 |
| 52-Week Range | 42.62 - 71.07 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 81.67(+74.03%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About PBH
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PBH stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PBH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PBH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PBH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PBH Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Gastrointestinal | $62.20M | 23.41% |
| Women's Health | $52.54M | 19.77% |
| Dermatologicals | $33.20M | 12.49% |
| Eye & Ear Care | $32.98M | 12.41% |
| Pain Relief | $26.80M | 10.09% |
| Oral Care | $22.36M | 8.41% |
| Cough, Cold & Allergy | $21.30M | 8.02% |
| Wellness, Sleep & Other | $14.33M | 5.39% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PBH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PBH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PBH
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $134.71M |
| VTIVanguard Morningstar Total Stock Market ETF | $78.47M |
| IWMiShares Russell 2000 ETF | $59.66M |
| VBVanguard Morningstar Small-Cap ETF | $56.36M |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $38.56M |
| VBRVanguard Morningstar Small-Cap Value ETF | $35.84M |
Estimated from each fund’s disclosed top holdings × AUM
PBH Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PBH’s recent data — informational, not investment advice
